Pharmaceutical Technology rounds up the key readouts from the 2026 Digestive Disease Week conference held in Chicago.

MSD has completed its acquisition of Terns Pharmaceuticals, expanding its pipeline of treatments for chronic myeloid leukaemia (CML).

Citius Oncology has secured up to $36.5m to accelerate the commercialisation of Lymphir, a recombinant fusion protein immune therapy.

Why does product loss occur in aseptic fill-finish, and how can a CDMO overcome material constraints to preserve as much drug product as possible?

Sunshine Lake Pharma, Lannett and its wholly owned subsidiary Lanexa Biologics have received FDA approval for Langlara.

As with its previous siRNA deal, Madrigal plans to explore whether gene-silencing could complement its lead drug Rezdiffra.

Novo Nordisk is set to launch Ozempic, its oral GLP-1 receptor agonist pill for adults with type 2 diabetes, in the US.

UCB’s Candid acquisition marks its second foray into the TCE space – closely following a $1.1bn licensing deal with TCE specialist, Antengene.

Latus Bio has closed a $97m Series A financing round to expand the reach of its gene therapies targeting wider patient groups.

Non-viral gene therapies may hold potential to overcome some safety, pricing and manufacturing hurdles linked to viral alternatives.

Seaport will use the funds for its neuropsychiatric drug pipeline, while Hemab will focus on bleeding disorder medicines.

Sales for Lilly blew past expectations in the quarter as demand for weight loss treatments showed no signs of abating.